DnB资产管理和头地技术提升了Geron的股份,Geron是一家以癌症治疗为重点的生物制药公司。 DnB Asset Management and Headlands Technologies boost stakes in Geron, a biopharmaceutical firm focused on cancer treatments.

DnB资产管理和头领技术大大增加了其对一家生物制药公司Geron Co.的股份。 DnB Asset Management and Headlands Technologies have significantly increased their stakes in Geron Co., a biopharmaceutical firm. Geron报告每股收入为0.04美元,与分析师的预期一致,市场上限为10.1亿美元。 Geron reported earnings of ($0.04) per share, aligning with analyst expectations, and has a market cap of $1.01 billion. 该公司的工作重点是研制用于治疗包括第3阶段试验中的关键药物Imetelstat在内的流星体血解恶性肿瘤的治疗方法。 The company focuses on developing therapeutics for myeloid hematologic malignancies, including its key drug, imetelstat, in Phase 3 trials.